Chrome Extension
WeChat Mini Program
Use on ChatGLM

Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.

AMERICAN JOURNAL OF CANCER RESEARCH(2019)

Cited 34|Views16
No score
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality among men and women in the United States. Its incidence has been on the rise, with a projected two-fold increase by 2030. PDAC carries a poor prognosis due to a lack of effective screening tools, limited understanding of pathophysiology, and ineffective treatment modalities. Recently, there has been a revolution in the world of oncology with the advent of novel treatments to combat this disease. However, the 5-year survival of PDAC remains unchanged at a dismal 8%. The aim of this review is to bring together several studies and identify various recent modalities that have been promising in treating PDAC.
More
Translated text
Key words
Pancreatic cancer,immunotherapy,cancer vaccine,BRCA,check point inhibitor,targeted therapy,hypoxia induced resistance
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined